RECRUITING

IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety. Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.

Official Title

Assessing Benefits and Harms of Cannabis Use in Patients Treated with Immunotherapy for Cancer: a Prospective Cohort Study

Quick Facts

Study Start:2025-01-02
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06206941

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * adult age of 21 years or older
  2. * cancer diagnosis and planning or using immunotherapy treatment,
  3. * pain and spend less than 50% in bed or chair
  4. * fluent in english language
  1. * use synthetic cannabis or only use Cannabidiol (CBD)
  2. * non users but used in the past 3 months
  3. * prior immunotherapy, Patients receiving immunosuppressants or organ transplant recipients.
  4. * Patients within 6 months of Hospice care.
  5. * Pain that limits movement to more than 50% of their day in bed or chair

Contacts and Locations

Study Contact

Rebecca L Ashare, PhD
CONTACT
716-829-6273
rlashare@buffalo.edu
Colleen K Kilanowski, MS
CONTACT
716-829-5977
ckk@buffalo.edu

Study Locations (Sites)

Oregon Health and Science University
Portland, Oregon, 97239
United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: State University of New York at Buffalo

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-02
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2025-01-02
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Cancer